

FORM 7**MONTHLY PROGRESS REPORT**Name of Listed Issuer: Stillcanna Inc. (the "Issuer").Trading Symbol: STILNumber of Outstanding Listed Securities: 110,874,727Date: December 31, 2019

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Company announced that it has begun shipping CBD Isolate to Bioscience Enterprises Inc. as outlined in the supply agreement dated May 28, 2019. Bioscience has operations in California, the United Kingdom and Ireland. The CBD Isolate shipment was successfully delivered from the Company's Polish

based NEXUS extraction facility to Biosciences' United Kingdom office. The Company anticipates ongoing monthly shipments to Biosciences offices globally. The Company announced that it has begun fulfilling an order from HempLabs Poland. HempLabs specializes in producing and selling various CBD-based products throughout Europe under the brand Cannabium. The Company anticipates fulfilling the HempLabs order by the end of the month.

The Company announced that it has begun shipping hemp biomass to Sequoya Cannabis in Poland as outlined in the supply agreement dated August 23, 2019. Sequoya has been successfully testing their CO2 extraction equipment. The Company anticipates shipping hemp to Sequoya on an ongoing monthly basis.

2. Provide a general overview and discussion of the activities of management.

The Company filed its Interim Consolidated Financial Statements and Management Discussion & Analysis for October 31, 2019 and posted on Sedar on December 31, 2019.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

The design of the NEXUS extraction facility requires an input of consistent hemp biomass, both in physical structure and in CBD concentration in order to monitor and optimize production efficiencies. The facility has the capacity to process 1080 kilos of blended hemp flower at a consistent 6% CBD biomass input into 40 Kilos of CBD Isolate every 12 hours. An average of 75% to 80% percent of the Cannabinoids in the hemp flower are captured through the extraction process.

The Company intends to blend its own biomass together with third party biomass to create a consistent input material of 6% CBD. If the Company can blend to a higher than 6% consistent input, it will increase extraction productivity. In Q1 of 2020 the Company plans to operate its NEXUS facility 7 days a week, 24 hours a day with the intention of increasing its extraction capabilities.

The Company's ORIGIN extraction facility in Romania, a joint venture with its partner Dragonfly Bioscience of the United Kingdom, has received positive feedback regarding its outstanding operational permits from various authorities including local and state fire marshals, the Environmental Agency, the Ministry of Health and the Anti-Drug Agency. All final requests for permits have been filed and the Company remains optimistic that it will receive all permits by January 15, 2020. In addition, the ORIGIN facility recently received and installed a second rotochrome, which has the ability to increase production capacity of THC-free CBD oil once fully operational.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None to report

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None to report

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None to report

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None to report

8. Describe the acquisition of new customers or loss of customers.

None to report

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

None to report

10. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

The Company's production staff in Poland's Nexus facility has grown to 20 employees, working 12-hour shifts on a two-day rotation during a seven-day work week.

11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None to report

12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None to report

13. Provide details of any securities issued and options or warrants granted.

None to report

14. Provide details of any loans to or by Related Persons.

None to report

15. Provide details of any changes in directors, officers or committee members.

None to report

16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

In January 2019, the European Commission updated the Novel Food Catalogue to state that extracts of Cannabis sativa L. and derived products containing cannabinoids are considered as novel foods, as a history of consumption has not been demonstrated. As a result, all extracts of hemp and derived products containing cannabinoids (including CBD) are now regarded by the European Commission as novel.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were/is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated 2020-01-09.

Joel Leonard
 Name of Director or Senior
 Officer
 DocuSigned by:
Joel Leonard
 Signature
 CFO
 Official Capacity

Issuer Details		For Month	Date of Report
Name of Issuer		End	20/01/09
Stillcanna Inc.		December	
		2019	
Issuer Address			
503-905 Pender St. W			
City/Province/Postal Code	Issuer Fax	Issuer Telephone No.	
Vancouver/BC/V6C1L6	No.	()	
	()		
Contact Name	Contact	Contact Telephone No.	
Joel Leonard	Position		
	CFO	604-239-0840	
Contact Email Address	Web Site Address		
joel@stillcanna.com	www.stillcanna.com		